Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study

Alessandra Vergori; Giulia Matusali; Eleonora Cimini; Licia Bordi; Paola Borrelli; Simone Lanini; Roberta Palazzi; Jessica Paulicelli; Davide Mariotti; Valentina Mazzotta; Stefania Notari; Rita Casetti; Massimo Francalancia; Silvia Rosati; Alessandra D’Abramo; Cosmina Mija; Paola Mencarini; Eugenia Milozzi; Emanuela Caraffa; Simona Sica; Elisabetta Metafuni; Federica Sorà; Angela Rago; Agostina Siniscalchi; Elisabetta Abruzzese; Mariagrazia Garzia; Giovanni Luzi; Roberta Battistini; Luca Prosperini; Antonella Cingolani; Enrico Girardi; Fabrizio Maggi; Andrea Antinori

doi:10.3390/vaccines12070784

Abstract

. We aimed to report the real-world use and outcomes over time in immunocompromised individuals receiving tixagevimab/cilgavimab (T/C) pre-exposure prophylaxis (PrEP).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vergori et al. (2024) studied this question.

synapsesocial.com/papers/68e60015b6db643587593e4e https://doi.org/10.3390/vaccines12070784

View Full Paper

Ask AI

Bookmark

Share

Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study

Abstract

Discussion

Cite This Study

Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading